Patients who were diagnosed with Kawasaki Disease (KD) (ICD-10 codes M303) between September 2010 and September 2017. Of these, we included patients who weighed 25 kg and more than 25kg and who received 1 g/kg and more than 1g/kg IVIG within 5 days of their initial hospital admission for KD. We divided the remaining cases into two groups of patients treated initially with 2 g/kg or 1 g/kg IVIG within 3 days, respectively.
Conditions
Interventions
children with KD weighing 25 kg and more treated with 1 g/kg IVIG
children with KD weighing 25 kg and more treated with 2 g/kg IVIG
Sponsors
The University of Tokyo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: We identified patients in the database who were diagnosed with KD (ICD-10 codes M303) between September 2010 and September 2017.Of these, we included patients who weighed 25 kg and more and who received 1 g/kg and more IVIG within 5 days of their initial hospital admission for KD.
Exclusion criteria
Exclusion criteria: Patients with atypical KD and who did not use IVIG within 5 days.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome was CAA at the time of discharge in the two groups. CAA was defined as the use of warfarin, clopidogrel, or receipt of cardiac catheterization, in addition to a diagnosis of CAA in the database. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes were the proportions of IVIG resistance, length of stay, medical costs, and IVIG-related side effects. IVIG resistance was defined as receiving IVIG at a total dose of 2.5 g/kg or more than 2.5 g/kg at intervals of more than 6 days. Additional treatments were defined as use of corticosteroids after day 5 at initial IVIG treatment, infliximab, plasma exchange, and cyclosporine. We also examined side effects attributed to IVIG treatments. | — |
Countries
Japan
Contacts
Public ContactNobuaki Michihata
The University of Tokyo Department of Health Services Research, Graduate School of Medicine
Outcome results
None listed